▶주메뉴 바로가기
▶본문 바로가기
Philips Korea advises patients with sleep disorders to seek active treatment such as CPAP therapy to manage conditions like sleep apnea Philips Korea, the local unit of multinational health technology company Philips, announced Wednesday the findings of a survey revealing that many Koreans struggle with poor sleep quality but do not seek active treatment for sleep disorders, particularly for breathing-related conditions like sleep apnea. The survey conducted by Hankook Research on behalf of Phil
Samsung Biologics, the biotech arm of Samsung Group, said Monday that it will participate in DCAT Week 2025, taking place March 17-20 in New York, as part of its efforts to expand its global business network. Organized annually by the Drug, Chemical & Associated Technologies Association, the event has a history of over 130 years and is a premier networking platform for the global pharmaceutical and biotech industries. Samsung Biologics has participated in DCAT Week every year since 2016, except
Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug Administration. Stoboclo is approved for treating postmenopausal osteoporosis in women, while Osenvelt is indicated for the prevention of skeletal-related complications in cancer patients with bone metastases and for giant cell tumors of bone. Both products have been approved for all indications covere
HanmiGlobal ranks 8th in global CM/PM sales
Hyundai Mobis wins cybersecurity certification in Europe
Hyundai Motor, EcoPro BM to develop LFP battery tech
Posco International joins global efforts for biodiversity
CJ's Miky Lee honored with Global Citizen Award
Incheon Airport tops ACI ratings for 3rd year in row